Search Page
Save citations to file
Email citations
Send citations to clipboard
Add to Collections
Add to My Bibliography
Create a file for external citation management software
Your saved search
Your RSS Feed
Filters
Results by year
Table representation of search results timeline featuring number of search results per year.
Year | Number of Results |
---|---|
2013 | 1 |
2014 | 1 |
2016 | 1 |
2024 | 0 |
Search Results
2 results
Results by year
Filters applied: . Clear all
Page 1
Benefits and Risks of Fosaprepitant in Patients Receiving Emetogenic Regimens.
Clin J Oncol Nurs. 2016 Oct 1;20(5):555-6. doi: 10.1188/16.CJON.555-556.
Clin J Oncol Nurs. 2016.
PMID: 27668376
Free PMC article.
Fosaprepitant dimeglumine (Emend IV) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regimens. ...
Fosaprepitant dimeglumine (Emend IV) is an IV antiemetic that may be beneficial to patients receiving highly emetogenic regime …
Evaluating the role of substance P in the growth of brain tumors.
Harford-Wright E, Lewis KM, Vink R, Ghabriel MN.
Harford-Wright E, et al.
Neuroscience. 2014 Mar 7;261:85-94. doi: 10.1016/j.neuroscience.2013.12.027. Epub 2013 Dec 27.
Neuroscience. 2014.
PMID: 24374326
Subsequently, A-375 human melanoma cell line was examined in vitro and found to express both SP and the NK1 receptor. Treatment with the NK1 receptor antagonist Emend IV resulted in decreased cell viability and an increase in cell death in this cell line in vitro. A …
Subsequently, A-375 human melanoma cell line was examined in vitro and found to express both SP and the NK1 receptor. Treatment with the NK1 …
Item in Clipboard
Cite
Cite